INTRODUCTION
Orlistat is a reduced form of the natural product lipstatin, which is an antiobesity agent marked under the tradename of Xenical approved by the FDA as the first over-the-counter weight-loss medication. 
RESULTS AND DISCUSSION
Firstly, the addition was mediated by 10 mol% of catalyst and the reaction condition (temperature and solvent) were optimized. The results are summarized in Table 1 . 
CONCLUSION
In conclusion, the have optimized the application of organocatalysts 1 as a perfect mediator in the enantioselective addition of oxime α-β-unsaturated aldehyde. The nature of the solvent is very important once the one-pot sequential Mukayama additions are under evaluation. 
